Cite
HARVARD Citation
Escobar, M. et al. (2023). Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of medical economics. pp. 574-580. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Escobar, M. et al. (2023). Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors. Journal of medical economics. pp. 574-580. [Online].